Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing
- 2 June 2016
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 107, 22-35
- https://doi.org/10.1016/j.lungcan.2016.05.024
Abstract
No abstract availableThis publication has 48 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)Cancer Treatment Reviews, 2013
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the LungJournal of Oncology Practice, 2012
- Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testingExpert Review of Molecular Diagnostics, 2012
- The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markersBritish Journal of Cancer, 2012
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practiceAnnals of Oncology, 2011
- Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3European Respiratory Journal, 2011
- Family Physician Involvement in Cancer Care Follow-up: The Experience of a Cohort of Patients With Lung CancerAnnals of Family Medicine, 2010
- Health state utilities for non small cell lung cancerHealth and Quality of Life Outcomes, 2008
- Quality of Life and Utility in Patients with Non-Small Cell Lung CancerPharmacoEconomics, 2001